Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients

Sun,Tao; Jiang,Daqing; Zhang,Liang; Su,Qinglong; Mao,Wanli; Jiang,Cui

doi:10.3892/ol.2015.3960

Expression profile of cathepsins indicates the potential of cathepsins B and D as prognostic factors in breast cancer patients

Authors:
- Tao Sun
- Daqing Jiang
- Liang Zhang
- Qinglong Su
- Wanli Mao
- Cui Jiang
View Affiliations

Affiliations: Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110000, P.R. China, Department of Breast Oncology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110000, P.R. China, Department of Medical Oncology, Central Hospital of Chaoyang, Chaoyang, Liaoning 100000, P.R. China, Department of Medical Oncology, Yongchuan People's Hospital, Yongchuan, Chongqing 404000, P.R. China
Published online on: November 23, 2015 https://doi.org/10.3892/ol.2015.3960
Pages: 575-583
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most prevalent types of cancer in women and contributes to 32% of all female cancer cases. Cathepsins, a family of proteins, are known to have a critical role in human cancers. However, previous studies on the systematic analysis of the role of cathepsin family members in breast cancer are limited. The aim of the present study was to identify biological markers to predict prognosis and treatment response of breast cancer patients, as well as to elucidate novel therapeutic targets. The present study analyzed the expression of six members of cathepsin family, including cathepsins B, G, D, K, L and V in 188 breast cancer tissue specimens using immunohistochemistry. The data showed that all members of the tested cathepsin families featured cytoplasmic staining. Notably, expression of cathepsin L was associated with advanced tumor stages, while cathepsins B and K expression levels were associated with positive estrogen receptor expression; in addition, cathepsin K expression was also demonstrated to be associated with progesterone receptor expression. Cathepsins V and D expression levels were found to be associated with breast cancer metastasis, while the expression levels of cathepsins B and D were associated with poor disease‑free survival in breast cancer patients. In addition, univariate analysis demonstrated that breast cancer metastasis to the bone and the expression of cathepsin B protein were associated with poor disease‑free survival. In conclusion, the results of the present study indicated that the altered expression of cathepsins, in particular cathepsins B and D, contributed to the progression of breast cancer and poor disease-free survival in breast cancer patients.

View Figures

View References

1	Figueroa-Magalhaes MC, Jelovac D, Connolly RM and Wolff AC: Treatment of HER2-positive breast cancer. Breast. 23:128–136. 2014. View Article : Google Scholar : PubMed/NCBI
2	Herold CI and Anders CK: New targets for triple-negative breast cancer. Oncology (Williston Park). 27:846–854. 2013.PubMed/NCBI
3	DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
4	Turk B, Turk D and Turk V: Lysosomal cysteine proteases: More than scavengers. Biochim Biophys Acta. 1477:98–111. 2000. View Article : Google Scholar : PubMed/NCBI
5	López-Otín C and Overall CM: Protease degradomics: A new challenge for proteomics. Nat Rev Mol Cell Biol. 3:509–519. 2002. View Article : Google Scholar : PubMed/NCBI
6	Gocheva V and Joyce JA: Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle. 6:60–64. 2007. View Article : Google Scholar : PubMed/NCBI
7	Chen JM, Dando PM, Rawlings ND, et al: Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem. 272:8090–8098. 1997. View Article : Google Scholar : PubMed/NCBI
8	Chen JM, Rawlings ND, Stevens RA and Barrett AJ: Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett. 441:361–365. 1998. View Article : Google Scholar : PubMed/NCBI
9	Im E and Kazlauskas A: The role of cathepsins in ocular physiology and pathology. Exp Eye Res. 84:383–388. 2007. View Article : Google Scholar : PubMed/NCBI
10	Tan GJ, Peng ZK, Lu JP and Tang FQ: Cathepsins mediate tumor metastasis. World J Biol Chem. 4:91–101. 2013.PubMed/NCBI
11	Mohamed MM and Sloane BF: Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer. 6:764–775. 2006. View Article : Google Scholar : PubMed/NCBI
12	Jedeszko C and Sloane BF: Cysteine cathepsins in human cancer. Biol Chem. 385:1017–1027. 2004. View Article : Google Scholar : PubMed/NCBI
13	Krepela E: Cysteine proteinases in tumor cell growth and apoptosis. Neoplasma. 48:332–349. 2001.PubMed/NCBI
14	Joyce JA and Hanahan D: Multiple roles for cysteine cathepsins in cancer. Cell Cycle. 3:1516–1619. 2004. View Article : Google Scholar : PubMed/NCBI
15	Gondi CS and Rao JS: Cathepsin B as a cancer target. Expert Opin Ther Targets. 17:281–291. 2013. View Article : Google Scholar : PubMed/NCBI
16	Frlan R and Gobec S: Inhibitors of cathepsin B. Curr Med Chem. 13:2309–2327. 2006. View Article : Google Scholar : PubMed/NCBI
17	Masson O, Bach AS, Derocq D, et al: Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity? Biochimie. 92:1635–1643. 2010. View Article : Google Scholar : PubMed/NCBI
18	Benes P, Vetvicka V and Fusek M: Cathepsin D-many functions of one aspartic protease. Crit Rev Oncol Hematol. 68:12–28. 2008. View Article : Google Scholar : PubMed/NCBI
19	Clezardin P: Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res. 13:2072011. View Article : Google Scholar : PubMed/NCBI
20	Huang L, Liu Z, Chen S, Liu Y and Shao Z: A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index. PLoS One. 8:e830812013. View Article : Google Scholar : PubMed/NCBI
21	Dian D, Heublein S, Wiest I, et al: Significance of the tumor protease cathepsin D for the biology of breast cancer. Histol Histopathol. 29:433–438. 2014.PubMed/NCBI
22	Kawakubo T, Yasukochi A, Toyama T, et al: Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer. Carcinogenesis. 35:714–726. 2014. View Article : Google Scholar : PubMed/NCBI
23	Bengsch F, Buck A, Günther SC, et al: Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene. 33:4474–4484. 2014. View Article : Google Scholar : PubMed/NCBI
24	Esteva FJ and Hortobagyi GN: Prognostic molecular markers in early breast cancer. Breast Cancer Res. 6:109–118. 2004. View Article : Google Scholar : PubMed/NCBI
25	Rochefort H, Garcia M, Glondu M, et al: Cathepsin D in breast cancer: Mechanisms and clinical applications, a 1999 overview. Clin Chim Acta. 291:157–170. 2000. View Article : Google Scholar : PubMed/NCBI
26	Tomoo K: Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor. Curr Top Med Chem. 10:696–707. 2010. View Article : Google Scholar : PubMed/NCBI
27	Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B and Turk D: Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochim Biophys Acta. 1824:68–88. 2012. View Article : Google Scholar : PubMed/NCBI
28	Hashida S, Kominami E and Katunuma N: Inhibitions of cathepsin B and cathepsin L by E-64 in vivo. II. Incorporation of [3H] E-64 into rat liver lysosomes in vivo. J Biochem. 91:1373–1380. 1982.PubMed/NCBI
29	Hara K, Kominami E and Katunuma N: Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages. FEBS Lett. 231:229–231. 1988. View Article : Google Scholar : PubMed/NCBI
30	Tsukuba T, Okamoto K, Yasuda Y, et al: New functional aspects of cathepsin D and cathepsin E. Mol Cells. 10:601–611. 2000. View Article : Google Scholar : PubMed/NCBI
31	Garcia M, Platet N, Liaudet E, et al: Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells. 14:642–650. 1996. View Article : Google Scholar : PubMed/NCBI
32	Vetvicka V and Fusek M: Procathepsin D as a tumor marker, anti-cancer drug or screening agent. Anticancer Agents Med Chem. 12:172–175. 2012. View Article : Google Scholar : PubMed/NCBI
33	Nicotra G, Castino R, Follo C, Peracchio C, Valente G and Isidoro C: The dilemma: Does tissue expression of cathepsin D reflect tumor malignancy? The question: Does the assay truly mirror cathepsin D mis-function in the tumor? Cancer Biomark. 7:47–64. 2010.
34	Markićević M, Kanjer K, Mandušić V, et al: Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up. Biomark Med. 7:747–758. 2013. View Article : Google Scholar : PubMed/NCBI
35	Zhong YJ, Shao LH and Li Y: Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol. 42:373–383. 2013.PubMed/NCBI
36	Nouh MA, Mohamed MM, El-Shinawi M, et al: A potential prognostic marker for inflammatory breast cancer. J Transl Med. 9:12011. View Article : Google Scholar : PubMed/NCBI
37	Deaton DN and Tavares FX: Design of cathepsin K inhibitors for osteoporosis. Curr Top Med Chem. 5:1639–1675. 2005. View Article : Google Scholar : PubMed/NCBI
38	Hoegl L, Korting HC and Klebe G: Inhibitors of aspartic proteases in human diseases: Molecular modeling comes of age. Pharmazie. 54:319–329. 1999.PubMed/NCBI
39	Withana NP, Blum G, Sameni M, et al: Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 72:1199–1209. 2012. View Article : Google Scholar : PubMed/NCBI
40	Frizler M, Stirnberg M, Sisay MT and Gutschow M: Development of nitrile-based peptidic inhibitors of cysteine cathepsins. Curr Top Med Chem. 10:294–322. 2010. View Article : Google Scholar : PubMed/NCBI